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Summary
The linkage of individuals with obesity and COVID-19 is controversial and lacks sys-
tematic reviews. After a systematic search of the Chinese and English language litera-
ture on COVID-19, 75 studies were used to conduct a series of meta-analyses on the
relationship of individuals with obesity–COVID-19 over the full spectrum from risk
to mortality. A systematic review of the mechanistic pathways for COVID-19 and
individuals with obesity is presented. Pooled analysis show individuals with obesity
were more at risk for COVID-19 positive, >46.0% higher (OR = 1.46; 95% CI,
1.30–1.65; p < 0.0001); for hospitalization, 113% higher (OR = 2.13; 95% CI,
1.74–2.60; p < 0.0001); for ICU admission, 74% higher (OR = 1.74; 95% CI,
1.46–2.08); and for mortality, 48% increase in deaths (OR = 1.48; 95% CI, 1.22–1.80;
p < 0.001). Mechanistic pathways for individuals with obesity are presented in depth
for factors linked with COVID-19 risk, severity and their potential for diminished
therapeutic and prophylactic treatments among these individuals. Individuals with
obesity are linked with large significant increases in morbidity and mortality from
COVID-19. There are many mechanisms that jointly explain this impact. A major con-
cern is that vaccines will be less effective for the individuals with obesity.
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1 | INTRODUCTION
For persons with coronavirus disease 2019 (COVID-19) caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there
appears to be a strong relationship between being an individual with
overweight or obesity and the risks of hospitalization and needing
treatment in intensive care units (ICUs). Emerging literature suggests
that adults with obesity under the age of 60 are more likely to be hos-
pitalized.1 The COVID-19 pandemic has occurred at a time when the
prevalence of individuals with overweight/obesity is increasing in vir-
tually all countries globally. In fact, almost all countries today have a
prevalence of individuals with overweight/obesity greater than
20%.2–4 To date, no country has experienced a reduction in the preva-
lence of individuals with overweight/obesity.
In addition, policy responses for mitigating COVID-19 are creat-
ing major economic hardships. The COVID-19 pandemic has brought
to all countries the need to restrict movement, implement social dis-
tancing and impede economic activities across a broad spectrum of
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nonessential occupations. These adjustments have caused food sys-
tem problems, including changes in food consumption and physical
activity patterns, and remote telework environments that may exacer-
bate current trends in the prevalence of individuals with obesity, while
another effect will be to increase the proportion food insecure and
also those stunted and malnourished. These changes have long-lasting
implications beyond the mitigation of the current SARS-CoV-2 spread
and may be detrimental to people's health.
The association between individuals with excessive body fat,
especially visceral adipose tissue; individuals with obesity; major car-
diometabolic problems, ranging from hypertension to cardiovascular
disease to type 2 diabetes (T2D); and a number of cancers is
strong.5–8 The underlying metabolic and inflammatory factors of indi-
viduals with obesity also play a considerable role in the manifestation
of severe lung diseases. Susceptibility to acute respiratory distress
syndrome (ARDS), the primary cause of COVID-19 mortality, is signifi-
cantly greater among individuals with obesity.9 Importantly, being an
individual with obesity independently increases the risk of influenza
morbidity and mortality,10 most likely through impairments in innate
and adaptive immune responses.11 Potentially the vaccines developed
to address COVID-19 will be less effective for individuals with obesity
due to a weakened immune response.
In this paper, we first highlight the epidemiological data that pro-
vide insight into the relationship between being an individual with
overweight/individuals with obesity and COVID-19, undertaking
when possible meta-analyses of the published data. We provide an
overview of the current understanding of how individuals with obesity
affect the immunological and physiological response to SARS-CoV-2.
We follow this with a discussion of the issues of income distribution,
food insecurity and the major dietary shifts we are seeing globally. For
the latter, we rely on reviews and reports from some key sources of
industry sales data, as no solid primary data sources are available. Our
discussion includes dietary and activity issues linked with COVID-19
that might exacerbate individuals with obesity and some of the poten-
tial policies that can address this issue.
2 | BACKGROUND: THE GLOBAL
PREVALENCE OF INDIVIDUALS WITH
OVERWEIGHT AND OBESITY
The prevalence of individuals with overweight/obesity is at an all-time
high and is increasing across the globe. This is true not only in higher
income countries but also in low- and middle-income countries with
high levels of undernutrition leading to the double burden of malnutri-
tion.4,12 Few low- and middle-income countries have a prevalence of
individuals with overweight/obesity less than 20% among their adult
populations. Figure 1 shows a map of the world in the 1990s and the
late 2010s.
A large proportion of the populations in higher income countries
are overweight or obese. As Figure 1 shows, few higher income coun-
tries have adult populations with a prevalence of overweight/obese
less than 70%. This prevalence is not declining in any country. In
higher income countries, the prevalence of individuals with
overweight/obesity was already high in the 1990s, and it has contin-
ued to increase. In fact, larger portions of their populations have
become individuals with morbid obesity with body mass indexes
(BMIs) over 35–40 kg m−2. In low- and middle-income countries out-
side of Latin America and a number of small islands, the growth in
individuals with overweight/obesity has occurred primarily in the past
several decades from 1990 to 2020 which we and many others have
documented.2,3,13–16 Further, evidence shows that >70% of the indi-
viduals with overweight/obesity live in low- or middle-income coun-
tries, and as country economies grow, the burden of individuals with
obesity shifts to the poor.17–19 In the Middle East and Latin America,
the prevalence of rates of individuals with obesity are among the
highest in the world.
Two related factors are equally important. First, we are finding
that much of the BMI increase accompanies an increase in central adi-
posity proxied by waist circumference at all ages compared with the
amount of such adiposity one or two decades earlier.20–22 Second,
across the globe, the economically poor are more prone to develop
obesity than are the rich.17–19,23
F IGURE 1 Prevalence of overweight and obesity based on 1990s
and late 2010s weight and height data
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3 | EPIDEMIOLOGICAL RELATIONSHIPS:
INDIVIDUALS WITH OVERWEIGHT AND
OBESITY AND COVID-19
This review study is exempted from IRB review, and there was no
public or patient involvement.
3.1 | Literature retrieval
We examined PubMed, Google Scholar, MedRxiv, BioRxiv, Wanfang
(for Chinese literature) and other literature search engines (e.g., China
National Knowledge Infrastructure Data and ICNARC) to systemati-
cally review all publications in Chinese or English that include data on
COVID-19 and BMI or individuals with obesity. We briefly reviewed
the abstracts and results and located 75 publications available by
15 July 2020 that presented data on the BMIs or BMI categories of
diagnosed COVID-19 patients. We excluded literature in other lan-
guages, as we read Chinese and English only. All of our authors
performed the literature searches and reviews. Table S1 presents the
search terms.
3.2 | Study characteristics
We found 1733 studies, 75 of which provided data we could use in
this review (Figure 2). All were conducted between January and June
2020, including five case–control studies, 33 retrospective or pro-
spective cohort studies and 37 observational cross-sectional studies.
Sample sizes varied from 24 to 109 367 diagnosed patients in more
than 10 countries in Asia, Europe and North and South America. In
total, we included 399 461 diagnosed patients in this study, about
55% of whom were male. Table S2 presents detailed demographic
data from the studies we used, including a few studies that had inade-
quate data for use in the meta-analysis. We used STATA (version
16, College Station, TX) to perform all random-effects meta-analysis
and used residual maximum likelihood to fit all models.24
3.3 | Being an individual with obesity and the risk of
COVID-19
We identified 20 studies that assessed the association between indi-
viduals with obesity and COVID-19, all but two of which showed that
individuals with obesity significantly increase the risk of COVID-19
(Table S3).25–43 One study in Denmark showed that the prevalence of
overweight and individuals with obesity was lower in SARS-CoV-2
positive cases than SARS-CoV-2 test-negative individuals (8.6%
vs. 9.9%).44 The results may be biased because body weight status
was determined at hospital discharge. A study used U.K. Biobank data
(n = 285 817) to show that overweight increased the risk of COVID-
19 by 44.0% (relative risk [RR] = 1.44; 95% CI, 1.08–1.92; p = 0.0100)
and individuals with obesity almost doubled the risk (RR = 1.97; 95%
F IGURE 2 Flowchart for meta-analysis of the obesity–COVID-19
relationship
F IGURE 3 Meta-analysis of the
association between individuals with obesity
and the risk of testing positive for COVID-19
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CI, 1.46–2.65; p < 0.0001), adjusted for age, sex, ethnicity and socio-
economic deprivation as measured by unemployment, assets and
household density.32 The authors tested only a small portion of indi-
viduals (0.5%) for COVID-19, a key limitation of this study. A better
way to calculate OR for this study is to compare the odds between
subjects who tested positive and those who tested negative. Our
pooled data analysis showed that the odds of individuals with obesity
being COVID-19 positive were 46.0% (OR = 1.46; 95% CI, 1.30–1.65;
p < 0.0001) higher than those of individuals who were not obese
(Figure 3).
3.4 | Being an individual with obesity and COVID-19
illness severity
Being an individual with obesity increases the odds of COVID-19
patients being hospitalized. Among diagnosed COVID-19 patients, the
prevalence of individuals with obesity in hospitalized patients was much
higher than that in nonhospitalized patients. For example, a report that
included 5700 patients with obesity in New York City45 showed that
41.7% of COVID-19 hospitalized patients were individuals with obesity,
whereas the average prevalence of individuals with obesity in
New York City was 22.0%.46 Many studies reported COVID-19 hospi-
talizations, but only a few reported the relationship between individuals
with obesity and hospitalization. We identified 19 studies that exam-
ined the relationship and included them in this analysis.1,28,38,40,44,47–58
Table S4 presents the results1,45,47,48,59,60; all showed a significantly
higher prevalence of individuals with obesity among hospitalized
patients than among patients not hospitalized or the general population.
The pooled OR was 2.13 (95% CI, 1.74–2.60; p < 0.0001) (Figure 4).
Among patients with symptoms, those with severe or critical con-
ditions had much higher BMIs and individuals with obesity prevalence
than the normal population or patients who were COVID-19
negative.32,61–70 Two studies showed that the odds of having COVID-
19 increased by 30% (OR = 1.30; 95% CI, 1.09–1.54; p = 0.0030)61
and by 38% (OR = 1.38; p < 0.0001),32 respectively, among the indi-
viduals with obesity (Table 1).
All studies reported that among those diagnosed, patients with
obesity were more likely to be admitted to ICUs.* However, the effect
sizes in the studies with smaller sample sizes were not statistically sig-
nificant.48,72,73 In the studies that found that being an individual with
obesity did not significantly increase the odds of being admitted to
the ICU, individuals with morbid obesity (defined as BMI ≥ 35) did sig-
nificantly increase the odds of ICU admittance. Our pooled data (from
22 studies) showed that individuals with obesity increased the odds
of being admitted to the ICU by 74% (OR = 1.68; 95% CI, 1.46–2.08;
p < 0.0001) (Figure 5 and Table S5).
Reports that had smaller sample sizes from the United Kingdom
and some other countries showed that patients with obesity had
higher but insignificant odds of invasive mechanical ventilation (IMV)
than patients without obesity.48,72,86 Reports from Mexico and some
U.S. cities showed significantly higher odds of IMV in patients with
obesity than in patients without obesity.† The pooled data (from
14 studies) showed a 66% increase in IMV in patients with obesity
(OR = 1.66; 95% CI, 1.38–1.99; p < 0.0001) (Figure 6 and Table S6).
3.5 | Being an individual with obesity and COVID-19
prognosis
The association between obesity and COVID-19 prognosis is com-
plex, because patients discharged from ICUs may be still hospital-
ized or deceased later. For example, 4.5% died after they were
discharged from ICU; 11.5% remained in the hospital after leaving
the ICU in one study.31 A few studies showed that individuals with
F IGURE 4 Meta-analysis of the association
between individuals with obesity and the risk of
hospitalization with COVID-19
*References 1, 27, 31, 41, 44, 48, 54, 72–85.
†References 27, 31, 55, 66, 73, 81, 87, 88.
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obesity may decrease in-hospital mortality.31,75,87,89 Some studies
showed that obesity may insignificantly decrease41,47,81,90 or
increase55,67,68,84,91–96 the odds of death among individuals with
obesity. The majority of studies showed that obesity significantly
increased the odds of death among COVID-19 patients with obe-
sity. The pooled data (from 35 studies) showed that patients with
obesity were more likely to have unfavourable outcomes with a
48% increase in deaths (OR = 1.48; 95% CI, 1.22–1.80; p < 0.001)
(Figure 7 and Table S7).‡ We excluded two studies that had very
large OR and very wide 95% CI, one study in China (OR = 32.08;
95% CI, 6.73–153)65 and one in Nevada (OR = 10.55; 95% CI,
1.07–104.45),106 from Figure 7, but included them in the meta-
analysis.
4 | WHY ARE INDIVIDUALS WITH OBESITY
AT SERIOUS RISK FOR COVID-19?
Being an individual with obesity is associated with numerous underly-
ing risk factors for COVID-19, including hypertension, dyslipidaemia,
type 2 diabetes (T2D) and chronic kidney or liver disease. Cor-
onaviruses are typically not associated with severe disease and were
mostly thought to cause only mild respiratory infections until the
emergence of the 2002 severe acute respiratory syndrome coronavi-
rus (SARS-CoV) in Guangdong, China. The SARS-CoV outbreak was
ultimately contained thanks to its low viral load within the beginning
stages of symptom onset, allowing time for identification and isolation
of infected individuals.107 The 2009 influenza pandemic, caused by an
outbreak of the upper respiratory influenza A H1N1 virus, identified
individuals with obesity as an independent risk factor for severe influ-
enza morbidity and mortality.10 Subsequently, emergence of the Mid-
dle East respiratory syndrome coronavirus (MERS-CoV) in 2012
exhibited high prevalence among individuals with obesity.108 The
growing evidence detailed above demonstrates that obesity increases
the risks of hospitalization, severity and in some cases death with viral
respiratory infections, increasing the likelihood that obesity may also
independently increase the risk for COVID-19, another respiratory
viral disease. Several reports summarize the current understanding of
the pathogenicity and immune response to SARS-CoV-2 based on
available data from animal and human studies.109,110 Importantly, the
mechanism(s) responsible for greater COVID-19 severity in individuals
with obesity remains unknown. However, insights from other viral
infections, like influenza, and epidemiological evidence offer some
understanding of how being an individual with obesity increases the
risk of COVID-19 severity (Figure 8). Considering the exponential rise
in the prevalence of individuals with obesity, understanding how
being an individual with obesity increases the risk for severe COVID-
19 is critical to ensure appropriate interventional and prophylactic
therapies against this novel coronavirus.
Figure 8 shows the effects of the physiological consequences of
obesity on COVID-19 clinical outcomes. These factors may also influ-
ence a vaccine response in individuals with obesity. There are other
underlying factors—individual, household and community that impact
significantly how we eat, drink and move, and we do not address their
indirect impacts on COVID-19.
4.1 | Individuals with obesity's metabolic and
physiological impairments linked to COVID-19
Being an individual with obesity is a major risk factor for severe cases
of certain infectious diseases, like influenza, hepatitis and nosocomial
infections.111,112 However, other infections, like tuberculosis,
community-acquired pneumonia and sepsis, have more favourable
clinical outcomes in adults with obesity compared with lean adults.113
This supports the ‘obesity paradox’ hypothesis, where underlying
characteristics of individuals with obesity influence the physiological
response to infection. As with influenza infections, being an individual
TABLE 1 Body mass index (BMI) (kg m−2) distributions among COVID-19 patients (mean with 95% CI or median with interquartile range)
First author N Mild Critical Average National71a
Chen 145 23.2 (21.7–25.7) 24.8 (23.1,27.0) 23.7 (21.7–27.0) 23.9
Peng 112 22.0 (20.0–24.0) 25.5 (23.0–27.5) 22.0 (20.0–25.0) 23.9
Liao 81 24.5 (22.3–27.7) 23.9 (20.0–27.3) 24.0 (21.5–27.3) 23.9
Wu 280 23.6 ± 3.2 25.8 ± 1.8 24.1 ± 3.0 23.9
Liu 30 22.0 ± 1.3 27.0 ± 2.5 22.7 ± 2.3 23.9
Li 182 24.8 ± 4.1 23.9
Bhatraju 24 33.2 ± 7.2 28.8
Simonnet 124 29.6 (26.4–36.4) 25.3
Argenziano 1000 28.6 (25.2–33.1) 29.4 (25.7–34.2) 28.6 (25.2–33.1) 25.3
Prats-Uribe 1039 29.2 ± 5.5 27.4
Raisi-Estabragh 669 28.2 ± 6.3 26.7
Ho 340 29.0 ± 5.3 27.3
aThe National mean BMI data come from the country of the study.
‡References 25, 27, 38, 40, 44, 47, 49, 57, 65, 97–105.
POPKIN ET AL. 5 of 17
with obesity appears to increase COVID-19 severity. Obesity is inher-
ently a metabolic disease characterized by alterations in systemic
metabolism, including insulin resistance, elevated serum glucose,
altered adipokines (e.g., increased leptin and decreased adiponectin)
and chronic low-grade inflammation.114,115 Strong evidence demon-
strates how hormone and nutrient dysregulation in individuals with
obesity can impair the response to infection.
Hyperglycaemia, a key hallmark of T2D, is highly associated with
individuals with obesity. Importantly, uncontrolled serum glucose has
been shown to significantly increase COVID-19 mortality.116 During
times of infection, uncontrolled serum glucose can impair immune cell
function either directly or indirectly via generation of oxidants and
glycation products.117 Similarly, both insulin and leptin signalling are
critical in the inflammatory effector response of T cells by up-
regulating cellular glycolysis,118,119 supporting the production of
effector cytokines such as IFN-γ and TNF-α. These metabolic factors
combine to influence immune cell metabolism,120 which dictates the
functional response to pathogens, such as SARS-CoV-2.
Dietary consumption of fatty acids can also influence inflamma-
tory responses. Prostaglandins, the derivatives of long chain fatty
acids, are acute phase pyrogens that initiate the local inflammatory
response during infection. Omega-3 polyunsaturated fatty acids can
induce anti-inflammatory responses through cyclooxygenase (COX)
activity, whereas omega-6 fatty acids mediate the pro-inflammatory
COX production of prostaglandins.121–123 Current dietary intakes
favour omega-6 fatty acids over omega-3s, with U.S. consumption
currently in a 10:1 ratio due to the widespread consumption of vege-
table oils.124 Fatty acid derivatives can directly influence COVID-19 in
individuals with obesity. Preclinical data suggest a role for fatty acid
derived pro-resolving lipid mediators, as they can be deficient in indi-
viduals with obesity and thus are not able to appropriately resolve
inflammatory responses during infection.125
Other fatty acids, such as cholesterol, are essential in the spread
of enveloped RNA viruses, like respiratory syncytial viruses and influ-
enza. SARS-CoV, the nearest relative to SARS-CoV-2, uses cholesterol
to facilitate viral budding following S protein binding of cellular ACE2
receptors, allowing the spread to neighbouring cells. Depletion of cho-
lesterol in ACE2 expressing cells results in markedly reduced viral S
protein binding.126 Being an individual with obesity also increases the
risk of COVID-19 severity among patients with metabolic associated
fatty liver disease, where adults with obesity had a greater than six
fold higher risk for severe COVID-19 regardless of age, sex or com-
orbidities, such as hypertension, diabetes and dyslipidaemia.127
Physical features of individuals with obesity also likely increase
COVID-19 severity and risk. Obstructive sleep apnoea and other
respiratory dysfunctions in the individuals with obesity often increase
risk of hypoventilation-associated pneumonia, pulmonary hyperten-
sion and cardiac stress.128 Large waist circumference and greater
body mass increase the difficulty of care in hospital settings for sup-
portive therapies, such as intubation, mask ventilation and prone
F IGURE 5 Meta-analysis of the
association between individuals with obesity
and the risk of being placed in an intensive
care unit (ICU)
F IGURE 6 Meta-analysis of the association between individuals
with obesity and the risk of administration of invasive mechanical
ventilation (IMV)
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positioning to help reduce abdominal tension and increase diaphragm
capacity.129 Thus, the prognoses of COVID-19 patients with obesity
may be complicated by the increased clinical care burden among this
already vulnerable group.
4.2 | Being an individual with obesity impairs the
immune response to SARS-CoV-2
Being an individual with obesity has modulatory effects on key
immune cell populations critical in the response to SARS-CoV-2.
Specifically, increased BMI is associated with greater frequency of the
anti-inflammatory CD4 T cell subsets Th2 and T regulatory cells.130
Increased anti-inflammatory cells may inhibit the ability to reduce the
infection, as inflammatory responses are needed to control viral
spread. Regulatory T cells (Tregs) primarily resolve immune cell medi-
ated inflammation following infection. Tregs from hyperinsulinaemic
mice with obesity have reduced interleukin 10 (IL-10) production131
and, despite being in higher abundance in the lungs during influenza
infections, are 40% less suppressive.132 Functional responses to RNA
viruses, like SARS-CoV-2, rely on type 1 inflammatory responses by
Th1 cells for protection with optimal anti-inflammatory Treg
F IGURE 8 Clinical manifestations
and mechanisms for COVID-19 risk in
individuals with obesity
F IGURE 7 Meta-analysis of the association
between individuals with obesity and mortality
for individuals with COVID-19
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responses for immune resolution following infection. Severe cases of
individuals with influenza and COVID-19 share remarkably similar reli-
ance on type I interferon activation, with TNF/IL-1β-driven inflamma-
tion present in severe but not mild cases.133 Any imbalance in these T
cell subsets or functions is likely to impair the immune response to
SARS-CoV-2.
A further imbalance in immune cell subsets occurs with accumula-
tion of pro-inflammatory cells, including macrophages, dendritic cells,
cytotoxic T cells and Th1 cells, in the adipose tissue of obese individ-
uals. This influx of immune cells contributes to the development of
insulin resistance and chronic inflammation.134 These pro-
inflammatory immune cells along with hypertrophic adipocytes are
responsible for increased serum inflammatory cytokines, such as IL-6,
C-reactive protein and type I and type III interferons.135,136 This
immune phenotype can be further distinguished between nondiabetic
and people with diabetes and obesity through increased Th17 inflam-
mation driven by impaired immune cell oxidation of fatty acid
metabolites.137,138
These changes in systemic immune cell populations and their
accumulation in adipose tissue have been proposed as key mediators
of COVID-19 severity in individuals with obesity.139 Recently, mice
with obesity infected with lymphocytic choriomeningitis virus (LCMV)
were shown to have increased LCMV viral titres and LCMV-specific
immune cells in white adipose tissue, which upon secondary infection
resulted in greater inflammation and mortality in mice with obesity
compared with mice that are lean.140 Accumulation of adipocytes and
adipocyte-like cells can increase immune activation and cytokine pro-
duction during coronavirus infection.141 In addition to being nutrient-
rich storage pools, lipid accumulation and adipocyte hypertrophy
might be an immune reservoir that in individuals with obesity
becomes saturated with pro-inflammatory immune cell subsets.
Alterations in immune cell frequencies in individuals with obesity
have been proposed for SARS-CoV-2 severity, which uses the
angiotensin-converting enzyme 2 (ACE2) for viral entry and is highly
expressed in vascular tissues like the lungs and adipose tissue.141 Viral
entry via ACE2 cleavage by the serine protease TMRPSS2 spike pro-
tein allows viral replication not only in the respiratory tract but also in
other tissues expressing ACE2, including the intestinal enterocytes,
liver, heart and kidneys.109,142 This mechanism is thought to drive
increased incidence of ischemic and coagulopathy conditions in
COVID-19 patients.
4.3 | Inflammatory considerations of COVID-19 in
individuals with obesity
ARDS and acute lung injury (ALI) are two of the primary causes of
morbidity and mortality among adults infected with SARS-CoV-2.143
Presentation of ARDS and ALI is characterized by respiratory failure
due to excessive pro-inflammatory cytokine production. This inflam-
matory state leads to extensive lung damage, hypoxemic respiratory
failure regardless of oxygen administration and pulmonary oedema
not caused by congestive heart failure.144 Patients who develop
ARDS are typically administered mechanical ventilation with positive
end-expiratory pressure and high FiO2. Currently, adults with obesity
infected with SARS-CoV-2 have higher burdens of mechanical respira-
tory therapy support and ARDS development.66
Gong et al. previously demonstrated that, compared with lean
adults (BMI 18.5–24.9), adults with obesity are more likely to develop
ARDS.9 A 2016 meta-analysis investigating how BMI influences
ARDS/ALI outcomes demonstrated significantly lower ARDS-related
mortality in adults with obesity compared with lean adults despite
confirming greater odds for developing ARDS.145 However, a retro-
spective multicentre study in Wuhan, China, found higher ARDS-
related mortality among COVID-19 patients, which was predicted by
elevated serum IL-6.143 Similarly, elevated IL-6 is a hallmark of severe
SARS-CoV,146 MERS-CoV147 and pandemic H1N1 influenza A viral
infections.148 Additionally, severe COVID-19 cases have been associ-
ated with lymphopenia149 and lower expression of IFN-γ by CD4 T
cells.150 IFN-γ is an important antiviral protein, and reduced produc-
tion of this cytokine in response to influenza has been documented
previously in both models of mice with obesity and human
populations with obesity.132,151
Men also experience a higher burden of COVID-19 than
women.59 Being a man with obesity increases aromatase activity,
which can convert testosterone to estradiol.152 Oestrogen receptor
signalling can subsequently down-regulate IL-6 expression through
inhibition of NF-κB,153 which has been shown to confer protective
effects against influenza A virus in women through stimulation of neu-
trophil and virus-specific CD8 T cell responses.154 Interestingly, how-
ever, men with obesity have impaired oestrogen receptor signalling,
which leads to increased androgenic hormones and elevated
oestrogen production from adipose tissue.155 Recently, androgen
depletion therapy has been shown to protect against COVID-19 in
male prostate cancer patients.156 However, more information is
needed to understand the mechanism of action of androgens and
androgen depletion therapy. Nonetheless, adequate control of pro-
and anti-inflammatory responses during SARS-CoV-2 infections is
critical to limit nonspecific tissue damage and subsequent develop-
ment of ARDS, which has a higher burden among COVID-19 cases
with obesity.
4.4 | Implications for treatment and vaccination
strategies for being an individual with obesity
Obesity may also impair therapeutic treatments during COVID-19
infections. ACE inhibitors, which are commonly used to treat hyper-
tension, may increase COVID-19 severity in T2D patients, especially
those with poorly controlled blood glucose.157 While discontinuing
use of ACE inhibitors is not advisable at this time due to offsetting
cardiovascular benefits,158 current clinical trials are investigating miti-
gation of the spread of SARS-CoV-2 through inhibition of ACE2
binding. How these treatments in patients with obesity contribute to
COVID-19 severity, however, will be a key question in their overall
effectiveness. The IL-6 receptor (IL-6R) antagonist tocilizumab may
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reduce IL-6 signalling in severe COVID-19 cases where cytokine
release syndrome is a major factor of mortality.159 As noted above,
chronic inflammation is a hallmark of individuals with obesity, which
includes elevated levels of IL-6. Preliminary data suggest tocilizumab
treatment can reduce fever and oxygen requirement.160 However,
subjects with obesity with chronically elevated IL-6 may not benefit
from acute treatment. Dexamethasone, a corticosteroid commonly
used for inflammatory treatment of arthritis, allergic reactions or other
immune inflammatory disorders, has been shown in preliminary data
to reduce mortality in severe COVID-19 patients by 8–26%.161 These
data from the RECOVERY trial provide evidence of reduced 28-day
mortality with treatment of 6-mg dexamethasone over a consecutive
10-day period during the symptomatic phase, resulting in inclusion of
dexamethasone as a treatment option under the National Health Ser-
vice COVID-19 treatment protocol,162 joining remdesivir as the only
approved treatment options for COVID-19. There remains limited
information on other treatments, such as statins, nonsteroidal anti-
inflammatory drugs and angiotensin receptor blockers, regarding their
effectiveness against COVID-19 in the individuals with obesity. Con-
sidering that almost all countries today have a prevalence of individ-
uals with overweight/obesity greater than 20% and that in certain
countries, such as the United States and the United Kingdom, two-
thirds of the population is overweight/obese, understanding how
these therapies work in the host with obesity is critical information to
determine their long-term effectiveness.
Importantly, being an individual with obesity has also been shown
to impair the development of immunological memory. Influenza vacci-
nation in adults with and without obesity results in equivalent
influenza-specific antibody titres at 30 days post vaccination, but anti-
body titres wane significantly more in adults with obesity compared
with adults who are lean at 1 year post vaccination.163 Compared with
influenza-vaccinated lean adults, vaccinated adults with obesity have
impaired CD4 and CD8 T cell production of key inflammatory cyto-
kines IFN-γ and granzyme B.151 Adults with obesity also have two
times greater odds of influenza or influenza-like illness despite a
robust antibody response.164 Preclinical evidence demonstrates that
adjuvant vaccines confer less protection against influenza viruses in
diet-induced mice that are obese.165 Similar impairments in vaccine
effectiveness have been reported individuals with obesity for
tetanus,166 hepatitis A and B and rabies.167
Data from recovered COVID-19 patients show greater than 95%
of infected patients develop neutralizing antibodies against SARS-
CoV-2. However, early evidence suggests a waning of antibody pro-
duction over a period of weeks to months,168 suggesting vaccines
strategies designed for antibody seroprotection may not have as long-
lasting effects. This fast decline in circulating neutralizing antibodies is
more similar to common coronaviruses as opposed to SARS-CoV,
which has a longer sustained level of antibody titres of 2 years.169
Promising data from multiple groups find cross-reactive T cell
responses in 70–100% of COVID-19 patients.170,171 Le Bert et al.
showed 36 convalescent COVID-19 patients all had CD4 and CD8 T
cells capable of recognizing and responding to the NP protein of
SARS-CoV2. Importantly, they demonstrate presence of long-lived
memory T cells in 23 patients who recovered from SARS-CoV.172 Sev-
eral other key papers find T cell mediated immune responses to
SARS-CoV-2 across cohorts, suggesting generation of memory T cell
populations is critical for any future COVID-19 vaccine.173 Unfortu-
nately, as T cell responses have been shown to be impaired in individ-
uals with obesity, this suggests that a future COVID-19 vaccine may
be less effective in an population with a high prevalence of individuals
with obesity. Therefore, it is urgent that any vaccine trials and studies
include BMI as a potential confounder for vaccine effectiveness and
protection.
5 | COVID-19 ECONOMIC EFFECTS: HOW
DOES THE PANDEMIC INDIRECTLY AFFECT
OUR DIETS AND WEIGHT GAIN?
COVID-19 has led not only to increased unemployment and income
insecurity but to many changes in food supplies. Many aspects of food
supply chains have been disrupted, and components of the food sys-
tem focused on restaurants and hotels have lost their demand and are
experiencing difficulty redirecting toward home consumption. Other
key aspects of food chains, especially in low- and middle-income
countries have been completely disrupted with impacts varying by
country and region. There is an expectation of a significant rise in stu-
nting and adult thinness is expected, especially in South Asia, a few
select other SE Asian countries (e.g., Indonesia) and much of sub-
Saharan Africa along with pockets of the poor in all other low- and
middle-income countries.174 The impact on not only malnutrition but
increased food insecurity for the large proportion of lower income
families is expected to be significant.174
One might suspect we would see a decline in obesity if the food
insecurity impacts the individuals with overweight and obesity in
many low- and middle-income countries. This truly depends on how
serious is the food insecurity and loss of income and how are diets
shifted, if at all. We will see diet shifts in not only how we eat and
drink but also how we move if inactivity grows greatly. If the diets
shifts to increased consumption of refined carbohydrates, fried food
and other unhealthy aspects of the traditional diet or to increased
highly or ultraprocessed food we may experience increases in the
prevalence of individuals with obesity. One can speculate but we truly
do not know. Surveys on this topic are not published to date. Similarly
studies in higher income countries suggest weight gains or no shift in
weight.175 At the same time, some studies from higher income coun-
tries suggest potential increases in obesity.175,176
While we do not have data on sales of ultraprocessed foods and
beverages, many reports both from organizations monitoring food
purchases and global company reports suggest that in higher and
middle-income countries access to fresh foods, especially fruits and
vegetables is impacted due to breakdowns in local supply chains, and
the demand for packaged processed food has increased, especially in
the ready-to-eat and -drink categories.8,177 These foods tend to be
ultraprocessed and high in energy density, saturated fat, sodium and
sugar. The attraction is partially that these foods require less storage
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and are highly palatable. In addition, they are relatively inexpensive
due to the large economies of scale in their production. Particularly
where costs loom greatly in food-purchasing decisions, as among the
lower income segments of the population, these cheaper products
may be consumed in much greater quantities. However,
ultraprocessed foods are a major contributor to obesity and other
non-communicable diseases (NCDs). The literature linking
ultraprocessed foods with adverse health outcomes is large and
consistent.178–195
Additionally, the lockdown and fear of contact with the virus
will likely have reduced walking and other movements among all
age groups while enhancing sedentary living, TV and computer and
video games. We would expect significant declines in energy
expenditures from this combination of reduced movement and
increased sedentary behaviours. Concurrently, the rapid increase in
consumption of ultraprocessed foods and reduced energy
expenditures in almost all low-, middle- and high-income countries
are expected to heighten the risks of overweight, obesity and
other NCDs.196
6 | DISCUSSION AND POLICY
IMPLICATIONS
It is clear that increasing prevalence of individuals with
overweight/obesity among adults and the elderly is a major worldwide
problem. Individual with overweight and obesity face a greater risk of
severe consequences from COVID-19, including hospitalization, inten-
sive clinical care requirements and death. Moreover, individuals with
obesity are likely to face reductions in the effectiveness of vaccines
through mechanisms similar to those responsible for greater primary
infection risk. Furthermore, it is quite possible that social distancing
and stay-at-home policies may exacerbate adverse weight and health
situations through their effects on dietary and physical activity pat-
terns. Governments must consider actions to address not only long-
term economic issues but also diet quality during this and future pan-
demics to build resilience.
The immunological impairments from individuals with obesity
demonstrate the convergence of chronic and infectious disease risks.
They expose a large portion of the world population with
overweight/obesity status to greater risk of pulmonary viral infections
like COVID-19. Given the expanding prevalence of individuals with
overweight/obesity, it is imperative to consider the consequences of
the related impaired immune responses during development of thera-
pies and vaccines. Additional research is needed to understand the
causal relationships. Limited information is available on how COVID-
19 is influenced by metabolic, hormonal or inflammatory factors, all of
which have been previously shown to influence responses to infection
in other disease contexts. The hidden factors of obesity, such as the
potential divergence in the host microbiome, genetic or epigenetically
inheritable traits or dietary patterns and insufficiencies in expanding
populations with obesity, may elucidate the difference between
severe and nonsevere COVID-19 cases. Further, it is entirely possible
that the current pandemic could unintentionally worsen NCDs in
adults with overweight/obesity status.
COVID-19 is an unparalleled event in modern human history.
It has changed human lives and societies entirely. On the one
hand, social distancing and stay-at-home policies have paused
many economic activities and have created tremendous fiscal and
health burdens for governments and individuals, especially the
poor. These measures have increased consumption of unhealthy
processed foods and have decreased physical activity. On the other
hand, being an individual with overweight/obesity increase the risk
of SARS-CoV-2 infection and worsen COVID-19 outcomes, as dis-
cussed above. To date over 600 000 people have died from
COVID-19 globally with over 14 million total cases. The disease
has directly or indirectly affected nearly every individual's life in
countries all over the world. We need interdisciplinary collaborative
efforts to tackle this disease. We also need to develop policies
regarding infectious diseases to maintain a sustainable environment
and healthy lifestyles.
As an aside, it is useful to note that China and several other Asian
countries such as South Korea and Vietnam all saw limited impacts of
COVID-19 and all have very low prevalence of individuals with over-
weight and obesity. One might speculate that the reduced prevalence
of individuals with obesity is linked with reduced risk and mortality for
these countries, but there are way too many other factors to accept
such speculation.
6.1 | Policy implications
Vaccination remains the best protection against infectious diseases
like COVID-19. Therapeutics targeted at limiting viral replication or
remediating complications of infection may help limit severe cases
and moderately reduce mortality. Public health experts agree that viral
spread will continue to cause tremendous health and economic prob-
lems until we reach vaccination and/or community-acquired herd
immunity. Current models project that intermittent times of social dis-
tancing and lockdown measures will be required until a viable vaccine
can be widely produced,197 and these measures are likely to extend
into the foreseeable future. This paper highlights another concern—
that is, vaccines may not be as effective in individuals with
overweight/obesity. Given the large prevalence of the world popula-
tion that is composed of individuals with overweight/obesity, it is
imperative that governments ensure that testing and research focus
not only on the general efficacy of vaccines and therapeutics but also
on how they will impact individuals with obesity.
Furthermore, we must carefully monitor and regulate the con-
sumption of ultraprocessed foods and beverages through fiscal poli-
cies such as taxation and regulating marketing and promotion of such
foods. If as expected this behaviour is increasing, it will exacerbate
other health concerns, including risks of increased adiposity and major
NCDs. When compounded with reduced physical activity and
increased sedentary behaviour, the risk of increased adiposity is
clearly an important concern. Finally, the poor around much of the
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globe also face increased hunger and with it the potential for elevated
stunting and its consequences, including the long-term risks of central
visceral adiposity and many NCDs. Increasing hunger and stunting can
have long-term adverse impacts on health and well-being in multiple
ways, and major policies to mitigate this effect are critical when
resources are available.
In addition to COVID-19's critical economic constraints, its
impacts on diets may pose lifelong risks to populations around the
globe. Food habits developed during this period, particularly the
intake of ultraprocessed foods, represent a major health risk. Exact
policy prescriptions will be country specific, and clearly, the concerns
for higher and middle-income countries will differ from those of low-
income countries. NCD and individuals with obesity risks are far more
predominant in the former, whereas the latter face high levels of the
double burden of malnutrition, in which slow declines in stunting are
likely to shift to increased stunting and wasting accompanied by rapid
increases in individuals with obesity.
Creative policies to reduce consumption of ultraprocessed foods
and increase consumption of healthier foods, such as legumes,
selected whole grains, vegetables and fresh fruits, are important for all
countries. A recent World Bank report suggests that the multipurpose
Chilean model effectively administers multiple regulations and laws
that reinforce each other and are impactful.12,198,199 It is quite that
likely Chile's policies could significantly reduce the current growth in
consumption of ultraprocessed foods. Moreover, a tax accompanying
purchases of those foods would potentially increase fiscal space in
countries suffering from the economic impacts of COVID-19, albeit
few countries have successfully allocated these resources for health
or nutrition programmes. Some countries are finding ways to provide
boxes of fresh vegetables and fruits to the elderly such as one pro-
gramme in several Chilean cities200; however, most low- and middle-
income countries do not have the resources for such efforts though
combined with taxation and marketing controls, such efforts would be
more feasible. All countries need to consider how to enhance con-
sumers' selections of healthy food options while reducing incentives
to purchase ultraprocessed foods and beverages. To date, no country
has combined these fiscal and regulatory policies. However, Israel's
Chilean-style warning labels and promotion of healthy eating comes
closest.201
The COVID-19 pandemic challenges all countries enormously.
Our systems, institutions, health and welfare will feel the impacts for
many years. The high prevalence of individuals with obesity exacer-
bates the threat to everyone's health, and the economic, social dis-
tancing and stay-at-home components compound the impacts. We
will need creative solutions quickly to prevent undesirable dietary pat-
terns and promote healthy eating, which is so critical to our future
health and for building resilience against future threats.
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